My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista Cubana de Medicina Tropical
Print version ISSN 0375-0760On-line version ISSN 1561-3054
Abstract
NAVIA MOLINA, Omar et al. Inmunogenicidad de la vacuna Heberbiovac-HB a las dosis de 10,5 y 2,5 m g en niños escolares de 6 a 9 años de edad. Rev Cubana Med Trop [online]. 1999, vol.51, n.1, pp.46-49. ISSN 0375-0760.
The Heberbiovac-HB recombinant hepatitis B vaccine was administered at dosages of 10.5 and 2.5 m g in 3 groups of children aged 6-9 with a vaccination schedule at 0, 1 and 6 months of age. The immunogenecity attained between dosages was compared. The seroconversion with protective titres obtained at 2 months varied from 88.9 % with 10 m g to 79.4 % with 2.5 m g, whereas at 7 months it was higher than 98 % in the 3 groups. The geometrical mean with 10 mg was 136.63 and 2 356.8 UI/L-1; with 5 m g, 77.62 and 1 958.9 UI/L-1; and with 2.5 m g, 32.15 and 376.3 UI/UL-1, at 2 and 7 months, respectively. A high immunogenic power of the vaccine is observed at dosages of 10 and 5 m g with similar results. In spite of the fact that the dosage of 2.5 m g is inmunogenic, the response is not desirable. These results state the possibility of using a lower dosage (5 m g) for a low risk infantile population, which favors the cost-benefit.
Keywords : VACCINES, SYNTHETIC [administration & dosage]; HEPATITIS B VIRUS [immunology]; HEPATITIS B VACCINES [immunology].